Currus Biologics
Utilizing its proprietary BEAT technology to develop CAR-T cell therapies for the treatment of solid tumor cancers, traditionally difficult to treat with current CAR-T cell therapies. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD40—60m (Dealroom.co estimates Jun 2021.)
Company register number 645510194
Melbourne Victoria (HQ)
Authorizing premium user...